Cargando…
Safety of primary immunization using inactivated SARS-CoV-2 vaccine (CoronaVac®) among population aged 3 years and older in a large-scale use: A multi-center open-label study in China
OBJECTIVE: To evaluate the safety of primary immunization using CoronaVac® among population aged 3 years and above in a large-scale use. METHOD: A multi-center open-label study was carried out in 11 provinces of China. Individuals aged 3 years and older who had no history of COVID-19 vaccination or...
Autores principales: | Yang, Haitao, Li, Zhen, Zhang, Ruizhi, Guo, Shicheng, Wang, Binbing, Fang, Xing, Zhang, Dongjuan, Zhang, Xiaoshu, Tong, Yeqing, Wang, Qing, Deng, Qiuyun, Sun, Zhaodan, Liu, Xiaoqiang, Gao, Yongjun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837223/ https://www.ncbi.nlm.nih.gov/pubmed/36658045 http://dx.doi.org/10.1016/j.vaccine.2023.01.020 |
Ejemplares similares
-
Boosting immunity after CoronaVac
por: Sester, Martina, et al.
Publicado: (2022) -
Immunogenicity of Mix-and-Match CoronaVac/BNT162b2 Regimen versus Homologous CoronaVac/CoronaVac Vaccination: A Single-Blinded, Randomized, Parallel Group Superiority Trial
por: Samoud, Samar, et al.
Publicado: (2023) -
CoronaVac efficacy data from Turkey
por: McMenamin, Martina E, et al.
Publicado: (2021) -
An Integrative Analysis of the Immune Features of Inactivated SARS-CoV-2 Vaccine (CoronaVac)
por: Jiang, Zhujun, et al.
Publicado: (2022) -
Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial
por: Li, Jingxin, et al.
Publicado: (2022)